Vivace Therapeutics Raises $35M in Series D Financing
Summary
In conjunction with the financing, Jake Simson, Ph.D., partner at RA Capital Management, has joined the company’s board of directors. The company intends to use the funds to support the continued clinical development of the its transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma. Led by Sofie Qiao, Ph.D., president and chief executive officer, Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. VT3989 is a novel small molecule cancer therapeutic that targets the Hippo pathway by inhibiting palmitoylation of members of the TEAD protein family. In addition to promising efficacy, VT3989 has demonstrated excellent safety in the Phase 1 trial, positioning the compound with a profile.